Bio-Techne (NASDAQ: TECH) reported Q4 EPS of $0.53, $0.03 better than the analyst estimate of $0.50. Revenue for the quarter came in at $317 million versus the consensus estimate of $315.54 million.

For earnings history and earnings-related data on Bio-Techne (TECH) click here.